Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8645946 | 1.00 | CTSL (0.45) | CTSLCTSBCTSSCASP1CYP3A4 | |
| SCHEMBL7282041 | 1.00 | CTSL (0.45) | CTSLCTSBCTSSCASP1CYP3A4 | |
| SCHEMBL7594853 | 0.89 | CASP1 (0.48) | CTSLCTSBCTSSCASP1CTRB1 | |
| SCHEMBL5329730 | 0.89 | CASP1 (0.48) | CTSLCTSBCTSSCASP1CTRB1 | |
| SCHEMBL6328905 | 0.89 | CASP1 (0.48) | CTSLCTSBCTSSCASP1CTRB1 | |
| SCHEMBL6577081 | 0.89 | CASP1 (0.48) | CTSLCTSBCTSSCASP1CTRB1 | |
| SCHEMBL7491284 | 0.89 | CASP1 (0.48) | CTSLCTSBCTSSCASP1CTRB1 | |
| SCHEMBL6577088 | 0.89 | CASP1 (0.48) | CTSLCTSBCTSSCASP1CTRB1 | |
| SCHEMBL5230909 | 0.82 | CASP1 (0.52) | CTSLCTSBCTSSCASP1CYP3A4 | |
| SCHEMBL5226937 | 0.81 | PPARA (0.55) | CTSLCTSBCTSSCASP1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0889036-B1 | HIV protease inhibitors | AGOURON PHARMA (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6693199-B2 | DEPROTECTING CARBAMATE GROUP AND AMIDATING IN PRESENCE OF SUCH AS HYDROXYBENZOTRIAZOLE HYDRATE PROMOTER | AGOURON PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030216569-A1 | Method of making HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2003-11-20 | — | — | US | disclosed |
| EP-0722439-B1 | HIV PROTEASE INHIBITORS | AGOURON PHARMA (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020077338-A1 | HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2002-06-20 | — | — | US | disclosed |
| US-6162812-A | Pharmaceutical compositions containing HIV protease inhibitors and methods of their use | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-0763017-B1 | N-(3-AMINO-2-HYDROXYBUTYL)SULPHONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITORS | AGOURON PHARMA (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-0889036-A1 | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5527829-A | VIRICIDES; TREATING AIDS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5461154-A | HIV protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077338-A1 | HIV protease inhibitors | PREP, PRSS1, SERPINB1 | CTSL 29/4885CTSB 14/4885CTSS 15/4885 |
| US-20030216569-A1 | Method of making HIV protease inhibitors | SERPINB1, PRSS1, PREP | CTSL 37/4885CTSB 21/4885CTSS 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.